A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure (CHF)

The Corteria-trial is a first-in-human, randomized, placebo-controlled, 3-part study designed to assess the safety, tolerability, and pharmacodynamics of escalating doses of COR-1167 in healthy subjects and in subjects with CHF. The study includes 3 parts; Part A, in which healthy subjects are dosed. Part B, in which HF- patients are dosed. Part C which will focus on the echocardiographic parameters, natriuresis, diuresis and renal function parameters in patients with HF.

Research Team:

PI: dr. J. Oosterhaven (ICON)
Sub-i: prof. Dr. A.A. Voors
Sub-i: drs. G.H.D. Voordes
Sub-i: drs. L.E.E.C. Zonneveld
Project coordinators: H. Renkema en A. Branderhorst.


People involved

Principal investigators

Adriaan Voors